Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | DDX3X | O00571 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658380 | 0.83 | DDX3X (0.71) | MAPTMTNR1BCDK8EPHX1DDX3X | |
| SCHEMBL3690365 | 0.82 | MAPT (0.59) | MAPTDDX3XNPC1 | |
| SCHEMBL10172965 | 0.81 | NPC1 (0.68) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8885278 | 0.81 | ALDH1A1 (0.52) | MAPTDDX3XSMN1; SMN2 | |
| SCHEMBL17976250 | 0.81 | MAPT (0.50) | MAPTMTNR1BCDK8EPHX1SMN1; SMN2 | |
| SCHEMBL24211435 | 0.80 | MAPT (0.61) | MAPTSMN1; SMN2RAB9AALOX15NPC1 | |
| SCHEMBL13753678 | 0.80 | KMT2A (0.68) | MAPTSMN1; SMN2RAB9AALOX15NPC1 | |
| Ammonia Solution, Strong SCHEMBL2058716 | 0.80 | NPC1 (0.66) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11908700 | 0.80 | GAA (0.66) | MAPTMTNR1BSMN1; SMN2RAB9APOLB | |
| SCHEMBL4588033 | 0.80 | EPHX1 (0.71) | MAPTEPHX1RAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | MAPT 1942/4885MTNR1B 1476/4885CDK8 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.